Older postmenopausal women who have
been on long-term hormone therapy since menopause
to prevent osteoporosis are faced with the decision
of changing their therapy in light of the results
of the Women's Health Initiative trial and new professional
guidelines. Their risk factors for osteoporosis
and fracture need to be evaluated together with
their bone mineral density. Effective treatment
options are available for the prevention of bone
loss and the treatment of osteoporosis.
Topics
covered in this program
- The considerations in altering
the management of an older postmenopausal
woman who has been receiving hormone
therapy.
- Nonpharmacologic measures to
reduce fracture risk and bone loss.
- Pharmacologic options when
switching therapy.
The American Medical Association is accredited by
the Accreditation
Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians.
The American Medical Association designates this
module for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Nonphysicians may receive a certificate of participation
for completing this activity.
The development of this CME web module was supported
in part through an independent education grant from
the Alliance for Better Bone Health and produced in
accordance with the AMA Standards for Industry-Supported
Multimedia Continuing Medical Education and Other
Communications.
|
